Analyst Ratings For CVS Health
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for CVS Health (NYSE:CVS) over the past three months, with the most recent ratings being more bullish. The average 12-month price target for CVS is $93.2, down from the previous $101.00, indicating a potential decrease in stock value. CVS Health operates a vast network of retail pharmacies, is a major pharmacy benefit manager, and owns a top-tier health insurer. The company's recent acquisition of Oak Street Health could synergize with its existing operations. Financially, CVS has shown solid revenue growth, exceptional net margin, and strong ROE and ROA, with a sound debt-to-equity ratio.
December 22, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have a mixed outlook on CVS Health, with a recent shift towards bullish ratings. The average price target has decreased to $93.2, suggesting a potential decline in stock price. CVS's strong financials and recent acquisition may influence future performance.
The decrease in the average price target to $93.2 from $101.00 suggests that analysts expect CVS's stock price to potentially decline in the short term. However, the company's strong financial performance and recent acquisition of Oak Street Health could provide positive momentum. The mixed analyst ratings, with a recent bullish trend, indicate uncertainty in the market's direction, but the overall financial health of CVS is robust, which may mitigate the negative impact of the lowered price target.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100